It’s the most commonly cultivated, trafficked and abused illicit drug worldwide, and there’s still a lot of social stigma attached to the recreational use of pot. But it’s slowly dawning on regulators in countries from Canada to the US to South Africa that by ignoring the clear medical benefits of marijuana, they may have thrown the baby out with the bathwater. Countries across Europe are now also opening their minds, laws and wallets to cannabis.
Rentschler Biopharma SE appoints Dr. Christian Hunzinger
AppointmentsRentschler Biopharma SE announced today the appointment of Dr. Christian Hunzinger as the new Senior Vice President Project Management, effective from January 15, 2019.
Novozymes partners with Carbios subsidiary Carbiolice
Latest NewsNovozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.
Biomarker predicts response to TNF blockers
Latest NewsA new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
Valbiotis appoints Josep Infesta
AppointmentsValbiotis, a French research and development company committed to preventing and combating metabolic diseases, today on 24 January the appointment of Josep Infesta as Head of Global Business Development.
The great green rush
BackgroundIt’s the most commonly cultivated, trafficked and abused illicit drug worldwide, and there’s still a lot of social stigma attached to the recreational use of pot. But it’s slowly dawning on regulators in countries from Canada to the US to South Africa that by ignoring the clear medical benefits of marijuana, they may have thrown the baby out with the bathwater. Countries across Europe are now also opening their minds, laws and wallets to cannabis.
UK launches new payment model for antimicrobials
Latest NewsIn order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
BioNtech swallows MAB Discovery antibody unit
Latest NewsImmunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discovery‘s antibody generation unit.
Clariant inks cellulosic biodiesel pact with ExxonMobil/REG
Latest NewsSwiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
IMI launches €80m call
Latest NewsThe Innovative Medicines Initiative II has earmarked €80m for pre-competetive research improving the pharmaceutical industry’s productivity.
AMR: Novo Holdings funds companies with €18m
Latest News